JP2016527263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527263A5 JP2016527263A5 JP2016530632A JP2016530632A JP2016527263A5 JP 2016527263 A5 JP2016527263 A5 JP 2016527263A5 JP 2016530632 A JP2016530632 A JP 2016530632A JP 2016530632 A JP2016530632 A JP 2016530632A JP 2016527263 A5 JP2016527263 A5 JP 2016527263A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- cancer
- dimethoxy
- pyridin
- dimethoxyquinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 95
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 230000001154 acute effect Effects 0.000 claims description 18
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- -1 1-Isopropylpiperidin-4-ylamino Chemical group 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 208000034578 Multiple myelomas Diseases 0.000 claims description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 13
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 13
- 208000029742 colonic neoplasm Diseases 0.000 claims description 13
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 12
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 11
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 11
- 206010029260 Neuroblastoma Diseases 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 10
- 208000000172 Medulloblastoma Diseases 0.000 claims description 10
- 229910017711 NHRa Inorganic materials 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000005017 glioblastoma Diseases 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 125000004001 thioalkyl group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 201000003444 follicular lymphoma Diseases 0.000 claims description 8
- 230000003827 upregulation Effects 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 7
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000002018 overexpression Effects 0.000 claims description 7
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 230000005945 translocation Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000005024 Castleman disease Diseases 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 206010018691 Granuloma Diseases 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 229960001101 ifosfamide Drugs 0.000 claims description 6
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 6
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 5
- LIDOPKHSVQTSJY-VMEIHUARSA-N (e)-3-(6-bromopyridin-2-yl)-2-cyano-n-[(1s)-1-phenylbutyl]prop-2-enamide Chemical compound N([C@@H](CCC)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=CC(Br)=N1 LIDOPKHSVQTSJY-VMEIHUARSA-N 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 4
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 101150017888 Bcl2 gene Proteins 0.000 claims description 4
- 101150035324 CDK9 gene Proteins 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 102000002435 Cyclin T Human genes 0.000 claims description 4
- 108010068106 Cyclin T Proteins 0.000 claims description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000636213 Homo sapiens Transcriptional activator Myb Proteins 0.000 claims description 4
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims description 4
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 108700020796 Oncogene Proteins 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 102100030780 Transcriptional activator Myb Human genes 0.000 claims description 4
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 210000001280 germinal center Anatomy 0.000 claims description 4
- 210000003780 hair follicle Anatomy 0.000 claims description 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims description 3
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 claims description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 3
- GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 3
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 208000029862 Barrett adenocarcinoma Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 3
- 206010015226 Erythema nodosum Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 3
- BMGQWWVMWDBQGC-UHFFFAOYSA-N LSM-1221 Chemical compound C1C(N2C3=CC=CC=C3C3=C4C(=O)NCC4=C4C5=CC=CC=C5N5C4=C32)OC5(C)C(OC)C1N(C)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-UHFFFAOYSA-N 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010024612 Lipoma Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 108091057508 Myc family Proteins 0.000 claims description 3
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- 208000000592 Nasal Polyps Diseases 0.000 claims description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 206010029488 Nodular melanoma Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 102000043276 Oncogene Human genes 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010053869 POEMS syndrome Diseases 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 102000003946 Prolactin Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 3
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000009453 Thyroid Nodule Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 206010051515 Vocal cord cyst Diseases 0.000 claims description 3
- 206010047675 Vocal cord polyp Diseases 0.000 claims description 3
- 206010047676 Vocal cord thickening Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 3
- 229940098174 alkeran Drugs 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000001028 anti-proliverative effect Effects 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims description 3
- 206010071578 autoimmune retinopathy Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 206010061004 benign soft tissue neoplasm Diseases 0.000 claims description 3
- 229960004395 bleomycin sulfate Drugs 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 208000002458 carcinoid tumor Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 208000012106 cystic neoplasm Diseases 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950006418 dactolisib Drugs 0.000 claims description 3
- 229960003603 decitabine Drugs 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 230000008482 dysregulation Effects 0.000 claims description 3
- 230000002500 effect on skin Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 210000000744 eyelid Anatomy 0.000 claims description 3
- 206010016629 fibroma Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011066 hemangioma Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000029824 high grade glioma Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 201000008632 juvenile polyposis syndrome Diseases 0.000 claims description 3
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000011614 malignant glioma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- 229950008814 momelotinib Drugs 0.000 claims description 3
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 201000000032 nodular malignant melanoma Diseases 0.000 claims description 3
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960003243 phenformin Drugs 0.000 claims description 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 3
- 208000010916 pituitary tumor Diseases 0.000 claims description 3
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
- 208000014515 polyp of vocal cord Diseases 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000004853 protein function Effects 0.000 claims description 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 3
- 201000002793 renal fibrosis Diseases 0.000 claims description 3
- 201000006845 reticulosarcoma Diseases 0.000 claims description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 3
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000023984 stomach polyp Diseases 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 206010043207 temporal arteritis Diseases 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000009174 transverse myelitis Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- SBPTXZKMIVTJST-UHFFFAOYSA-N 2-[2-[(1-acetylpiperidin-4-yl)amino]-4-methoxyphenyl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound C(C)(=O)N1CCC(CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC SBPTXZKMIVTJST-UHFFFAOYSA-N 0.000 claims description 2
- DBGOCFILRTWEJF-UHFFFAOYSA-N 2-[2-[(1-benzylpiperidin-4-yl)amino]-4-methoxyphenyl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound C(C1=CC=CC=C1)N1CCC(CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC DBGOCFILRTWEJF-UHFFFAOYSA-N 0.000 claims description 2
- SNTRDVMTVOSMGQ-UHFFFAOYSA-N 2-[2-[(4,4-dimethylcyclohexyl)amino]-4-methoxyphenyl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound CC1(CCC(CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)C SNTRDVMTVOSMGQ-UHFFFAOYSA-N 0.000 claims description 2
- JYOPVHKBVGAHEH-UHFFFAOYSA-N 2-[3-[(1-acetylpiperidin-4-yl)amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound C(C)(=O)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC JYOPVHKBVGAHEH-UHFFFAOYSA-N 0.000 claims description 2
- NDNYZFZVPVZQHR-UHFFFAOYSA-N 2-[3-[[1-(2,2-dimethylpropanoyl)piperidin-4-yl]amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(C(C)(C)C)=O)=O NDNYZFZVPVZQHR-UHFFFAOYSA-N 0.000 claims description 2
- ZDURTCGYJZVAJA-UHFFFAOYSA-N 2-[3-[[1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound OC(CN1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)(C)C ZDURTCGYJZVAJA-UHFFFAOYSA-N 0.000 claims description 2
- PWRDSOICASXEQD-UHFFFAOYSA-N 2-[3-[[1-(2-hydroxypropanoyl)piperidin-4-yl]amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound OC(C(=O)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)C PWRDSOICASXEQD-UHFFFAOYSA-N 0.000 claims description 2
- CMXWHRZMCXGREU-UHFFFAOYSA-N 2-[4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]piperidin-1-yl]-N,N-dimethyl-2-oxoacetamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(C(=O)N(C)C)=O)=O CMXWHRZMCXGREU-UHFFFAOYSA-N 0.000 claims description 2
- UVBDDPVKSPDORX-UHFFFAOYSA-N 2-[4-chloro-2-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound ClC1=CC(=C(C=C1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)NC1CCN(CC1)C(C)C UVBDDPVKSPDORX-UHFFFAOYSA-N 0.000 claims description 2
- CXKSHDBVZSFBNF-UHFFFAOYSA-N 2-[4-chloro-2-[[1-(2-methylpropanoyl)piperidin-4-yl]amino]phenyl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound ClC1=CC(=C(C=C1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)NC1CCN(CC1)C(C(C)C)=O CXKSHDBVZSFBNF-UHFFFAOYSA-N 0.000 claims description 2
- WZSUDMPYGQVIBO-UHFFFAOYSA-N 2-[5-(2-hydroxyethoxy)-3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound OCCOC=1C=C(C(=NC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)NC1CCN(CC1)C(C)C WZSUDMPYGQVIBO-UHFFFAOYSA-N 0.000 claims description 2
- QUOPBDVIADVQSJ-UHFFFAOYSA-N 2-[5-(2-hydroxyethoxy)-3-[[1-(2-methylpropanoyl)piperidin-4-yl]amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound OCCOC=1C=C(C(=NC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)NC1CCN(CC1)C(C(C)C)=O QUOPBDVIADVQSJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- KIXXEUQUJMPDMI-UHFFFAOYSA-N 4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]-N,N-dimethylpiperidine-1-carboxamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(=O)N(C)C)=O KIXXEUQUJMPDMI-UHFFFAOYSA-N 0.000 claims description 2
- RSURNKWZWJSBSJ-UHFFFAOYSA-N 4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]-N-ethylpiperidine-1-carboxamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(=O)NCC)=O RSURNKWZWJSBSJ-UHFFFAOYSA-N 0.000 claims description 2
- HIYKSKWCVNHSRL-UHFFFAOYSA-N 4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]-N-propan-2-ylpiperidine-1-carboxamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(=O)NC(C)C)=O HIYKSKWCVNHSRL-UHFFFAOYSA-N 0.000 claims description 2
- LJFVTAVIXRRYCD-UHFFFAOYSA-N 4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]piperidine-1-carboxamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(=O)N)=O LJFVTAVIXRRYCD-UHFFFAOYSA-N 0.000 claims description 2
- FSBQQKKGLLLTDN-UHFFFAOYSA-N 5,7-dimethoxy-2-[2-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC1=C(C=CC=C1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC FSBQQKKGLLLTDN-UHFFFAOYSA-N 0.000 claims description 2
- DKIMPRBOZQMKQN-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-(2-morpholin-4-ylethylamino)pyridin-2-yl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NCCN1CCOCC1)=O DKIMPRBOZQMKQN-UHFFFAOYSA-N 0.000 claims description 2
- DNQOIQIGJVKLTP-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[(1-methylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C)=O DNQOIQIGJVKLTP-UHFFFAOYSA-N 0.000 claims description 2
- UEWHPCJVTBHWDG-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[(1-methylpyrrolidin-3-yl)methylamino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NCC1CN(CC1)C)=O UEWHPCJVTBHWDG-UHFFFAOYSA-N 0.000 claims description 2
- GBUYQKXBEUTGAZ-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]-5-[2-[(1-propan-2-ylpiperidin-4-yl)amino]ethoxy]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C(=NC=C(C=1)OCCNC1CCN(CC1)C(C)C)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC GBUYQKXBEUTGAZ-UHFFFAOYSA-N 0.000 claims description 2
- GQNFCEKLEMRUFH-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C=C(C=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC GQNFCEKLEMRUFH-UHFFFAOYSA-N 0.000 claims description 2
- NTZPUGGEWSDDTO-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC NTZPUGGEWSDDTO-UHFFFAOYSA-N 0.000 claims description 2
- UUCTYXGHEDUYFW-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[3-(propan-2-ylamino)propylamino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)NCCCNC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC UUCTYXGHEDUYFW-UHFFFAOYSA-N 0.000 claims description 2
- RRAWAUACYGRMOW-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NC1CCN(CC1)C(C(F)(F)F)=O)=O RRAWAUACYGRMOW-UHFFFAOYSA-N 0.000 claims description 2
- LADYAEMDZCIDGE-UHFFFAOYSA-N 5,7-dimethoxy-2-[3-[[1-(2-methylpropanoyl)piperidin-4-yl]amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C(C)C)(=O)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC LADYAEMDZCIDGE-UHFFFAOYSA-N 0.000 claims description 2
- SQEKCGLRFKTWFV-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(1-methylpiperidin-4-yl)sulfinylphenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)S(=O)C1CCN(CC1)C)=O SQEKCGLRFKTWFV-UHFFFAOYSA-N 0.000 claims description 2
- GXBJLTNYYBBRRG-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(2-morpholin-4-ylethylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCN1CCOCC1)=O GXBJLTNYYBBRRG-UHFFFAOYSA-N 0.000 claims description 2
- JJJRUWQTEAHDNU-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(2-piperazin-1-ylethylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCN1CCNCC1)=O JJJRUWQTEAHDNU-UHFFFAOYSA-N 0.000 claims description 2
- VRPPMTAYQNQJHF-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(2-piperidin-1-ylethylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCN1CCCCC1)=O VRPPMTAYQNQJHF-UHFFFAOYSA-N 0.000 claims description 2
- HICXWOVUTQDFJP-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(2-pyrrolidin-1-ylethylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCN1CCCC1)=O HICXWOVUTQDFJP-UHFFFAOYSA-N 0.000 claims description 2
- RTBZZWQLIQGZGR-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(3-morpholin-4-ylpropylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCCN1CCOCC1)=O RTBZZWQLIQGZGR-UHFFFAOYSA-N 0.000 claims description 2
- HXDDMBWQYOUENN-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(3-piperazin-1-ylpropylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCCN1CCNCC1)=O HXDDMBWQYOUENN-UHFFFAOYSA-N 0.000 claims description 2
- ZTDGSUXLPHGOIG-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(3-pyrrolidin-1-ylpropylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCCN1CCCC1)=O ZTDGSUXLPHGOIG-UHFFFAOYSA-N 0.000 claims description 2
- NXIMDRQEMSXXJJ-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(4-methylpiperazine-1-carbonyl)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)C(=O)N1CCN(CC1)C)=O NXIMDRQEMSXXJJ-UHFFFAOYSA-N 0.000 claims description 2
- VCRIDMNLYDGCNM-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-(oxan-4-ylamino)phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NC1CCOCC1)=O VCRIDMNLYDGCNM-UHFFFAOYSA-N 0.000 claims description 2
- FRAHQMXXLOFANF-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NC1CCN(CC1)C)=O FRAHQMXXLOFANF-UHFFFAOYSA-N 0.000 claims description 2
- SLKWOQXQKFHEEL-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpiperidin-4-yl)methylamino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCC1CCN(CC1)C)=O SLKWOQXQKFHEEL-UHFFFAOYSA-N 0.000 claims description 2
- RWERJRGENPUSFI-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpyrrolidin-3-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NC1CN(CC1)C)=O RWERJRGENPUSFI-UHFFFAOYSA-N 0.000 claims description 2
- PRDGUEJBCFBYCA-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpyrrolidin-3-yl)methylamino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCC1CN(CC1)C)=O PRDGUEJBCFBYCA-UHFFFAOYSA-N 0.000 claims description 2
- JIXFRGMHTPAYRA-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC JIXFRGMHTPAYRA-UHFFFAOYSA-N 0.000 claims description 2
- ZVRPFHROTNETHL-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-propan-2-ylpyrrolidin-2-yl)methylamino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1C(CCC1)CNC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC ZVRPFHROTNETHL-UHFFFAOYSA-N 0.000 claims description 2
- KLAKHNSPJKACIS-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[(1-propan-2-ylpyrrolidin-3-yl)methylamino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CC(CC1)CNC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC KLAKHNSPJKACIS-UHFFFAOYSA-N 0.000 claims description 2
- RKPTZXHUACNXOL-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[2-(4-methylpiperazin-1-yl)ethylamino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)NCCN1CCN(CC1)C)=O RKPTZXHUACNXOL-UHFFFAOYSA-N 0.000 claims description 2
- NQWZCMZIWNEEPG-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[2-(4-propan-2-ylpiperazin-1-yl)ethylamino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCN(CC1)CCNC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC NQWZCMZIWNEEPG-UHFFFAOYSA-N 0.000 claims description 2
- RYWODPWFARQXNZ-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[2-(propan-2-ylamino)ethylamino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)NCCNC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC RYWODPWFARQXNZ-UHFFFAOYSA-N 0.000 claims description 2
- CTXMEANYXDWGLQ-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[3-(propan-2-ylamino)propylamino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)NCCCNC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC CTXMEANYXDWGLQ-UHFFFAOYSA-N 0.000 claims description 2
- KBORRYSLKHTZBE-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[[1-(2-methylpropanoyl)piperidin-4-yl]amino]phenyl]-1h-quinazolin-4-one Chemical compound C=1C(OC)=CC=C(C=2NC3=CC(OC)=CC(OC)=C3C(=O)N=2)C=1NC1CCN(C(=O)C(C)C)CC1 KBORRYSLKHTZBE-UHFFFAOYSA-N 0.000 claims description 2
- JFGGFHCHXJTZIP-UHFFFAOYSA-N 5,7-dimethoxy-2-[4-methoxy-2-[methyl-(1-methylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=C(C=C(C=C1)OC)N(C1CCN(CC1)C)C)=O JFGGFHCHXJTZIP-UHFFFAOYSA-N 0.000 claims description 2
- HWUXBRAFKALCRE-UHFFFAOYSA-N 5,7-dimethoxy-2-[5-[2-(propan-2-ylamino)ethoxy]-3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)NCCOC=1C=C(C(=NC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)NC1CCN(CC1)C(C)C HWUXBRAFKALCRE-UHFFFAOYSA-N 0.000 claims description 2
- MRWBCPHRQHXXKU-UHFFFAOYSA-N 5,7-dimethoxy-2-[5-methoxy-2-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC1=C(C=C(C=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC MRWBCPHRQHXXKU-UHFFFAOYSA-N 0.000 claims description 2
- YDHHLRKQKPISHH-UHFFFAOYSA-N 5,7-dimethoxy-2-[5-methoxy-3-[(1-methylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=C(C=C1NC1CCN(CC1)C)OC)=O YDHHLRKQKPISHH-UHFFFAOYSA-N 0.000 claims description 2
- IRBZFCJGVZBMBL-UHFFFAOYSA-N 5,7-dimethoxy-2-[5-methoxy-3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C(=NC=C(C=1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC IRBZFCJGVZBMBL-UHFFFAOYSA-N 0.000 claims description 2
- USTNZWUXDAFILO-UHFFFAOYSA-N 5,7-dimethoxy-2-[5-methoxy-3-[[1-(2-methylpropanoyl)piperidin-4-yl]amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C(C)C)(=O)N1CCC(CC1)NC=1C(=NC=C(C=1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC USTNZWUXDAFILO-UHFFFAOYSA-N 0.000 claims description 2
- DZTLXJNZCWNEKX-UHFFFAOYSA-N 5-methoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-pyrido[3,4-d]pyrimidin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C(=NC=CC=1)C=1NC(C2=C(N=1)C=NC=C2OC)=O DZTLXJNZCWNEKX-UHFFFAOYSA-N 0.000 claims description 2
- XRIRLKKIDMDDEW-UHFFFAOYSA-N 5-methoxy-7-[(4-methoxyphenyl)methylamino]-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)(C)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)NCC1=CC=C(C=C1)OC XRIRLKKIDMDDEW-UHFFFAOYSA-N 0.000 claims description 2
- HXNHITRUDFCBDG-UHFFFAOYSA-N 7-(ethylamino)-5-methoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound C(C)NC1=CC(=C2C(NC(=NC2=C1)C1=NC=CC=C1NC1CCN(CC1)C(C)C)=O)OC HXNHITRUDFCBDG-UHFFFAOYSA-N 0.000 claims description 2
- UOYKOVZSSUBUFL-UHFFFAOYSA-N 7-amino-5-methoxy-2-[3-[(1-propan-2-ylpiperidin-4-yl)amino]pyridin-2-yl]-3H-quinazolin-4-one Chemical compound NC1=CC(=C2C(NC(=NC2=C1)C1=NC=CC=C1NC1CCN(CC1)C(C)C)=O)OC UOYKOVZSSUBUFL-UHFFFAOYSA-N 0.000 claims description 2
- NULLYCCYJCWKIZ-IYBDPMFKSA-N COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=C(C=C1N[C@H]1CC[C@H](CC1)NC(C(C)C)=O)OC)=O Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=C(C=C1N[C@H]1CC[C@H](CC1)NC(C(C)C)=O)OC)=O NULLYCCYJCWKIZ-IYBDPMFKSA-N 0.000 claims description 2
- SMBXQRIMRZIKLH-UHFFFAOYSA-N COC1=CC(=C(C=C1)C1=NC2=CC=CC=C2C(N1)=O)NCCCN1C(CNCC1)C Chemical compound COC1=CC(=C(C=C1)C1=NC2=CC=CC=C2C(N1)=O)NCCCN1C(CNCC1)C SMBXQRIMRZIKLH-UHFFFAOYSA-N 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 206010023125 Jarisch-Herxheimer reaction Diseases 0.000 claims description 2
- XMGBAHRANNQHFL-UHFFFAOYSA-N N-[2-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]ethyl]-2-methylpropanamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NCCNC(C(C)C)=O)=O XMGBAHRANNQHFL-UHFFFAOYSA-N 0.000 claims description 2
- KVVSKTHZLOIVFH-UHFFFAOYSA-N N-[3-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]propyl]-2-methylpropanamide Chemical compound COC1=C2C(NC(=NC2=CC(=C1)OC)C1=NC=CC=C1NCCCNC(C(C)C)=O)=O KVVSKTHZLOIVFH-UHFFFAOYSA-N 0.000 claims description 2
- CQQYCMANJFCQGW-WKILWMFISA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC1=C(C=CC(=C1)OC)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC CQQYCMANJFCQGW-WKILWMFISA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 208000029443 keratinization disease Diseases 0.000 claims description 2
- SNOVSDAIVFJLQI-UHFFFAOYSA-N methyl 2-[4-[[2-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)pyridin-3-yl]amino]piperidin-1-yl]-2-oxoacetate Chemical compound COC(C(=O)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC)=O SNOVSDAIVFJLQI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000025303 orbit neoplasm Diseases 0.000 claims description 2
- 201000000890 orbital cancer Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000004253 NUT midline carcinoma Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000000716 merkel cell Anatomy 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 241000579048 Merkel cell polyomavirus Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- ODAQFXPQVNEBKC-UHFFFAOYSA-N 2-[3-[[1-(1-hydroxy-2-methylpropan-2-yl)piperidin-4-yl]amino]pyridin-2-yl]-5,7-dimethoxy-3H-quinazolin-4-one Chemical compound OCC(C)(C)N1CCC(CC1)NC=1C(=NC=CC=1)C1=NC2=CC(=CC(=C2C(N1)=O)OC)OC ODAQFXPQVNEBKC-UHFFFAOYSA-N 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860403P | 2013-07-31 | 2013-07-31 | |
| US61/860,403 | 2013-07-31 | ||
| PCT/IB2014/002510 WO2015015318A2 (en) | 2013-07-31 | 2014-07-30 | Novel quinazolinones as bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527263A JP2016527263A (ja) | 2016-09-08 |
| JP2016527263A5 true JP2016527263A5 (enExample) | 2017-09-07 |
| JP6542212B2 JP6542212B2 (ja) | 2019-07-10 |
Family
ID=52432501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530632A Active JP6542212B2 (ja) | 2013-07-31 | 2014-07-30 | ブロモドメイン阻害剤としての新規キナゾリノン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9855271B2 (enExample) |
| EP (1) | EP3027604B1 (enExample) |
| JP (1) | JP6542212B2 (enExample) |
| KR (1) | KR20160038008A (enExample) |
| CN (1) | CN105593224B (enExample) |
| AU (1) | AU2014298051B2 (enExample) |
| CA (1) | CA2919948C (enExample) |
| EA (1) | EA201690087A1 (enExample) |
| IL (1) | IL243479B (enExample) |
| WO (1) | WO2015015318A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| EP2968360B1 (en) | 2013-03-14 | 2021-01-20 | ConverGene LLC | Quinolinone derivatives for the inhibition of bromodomain-containing proteins |
| CN105407888B (zh) | 2013-06-21 | 2019-05-21 | 齐尼思表观遗传学有限公司 | 新双环溴结构域抑制剂 |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| EP3125896A2 (en) * | 2014-04-04 | 2017-02-08 | Constellation Pharmaceuticals, Inc. | EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| CN112535685A (zh) * | 2015-05-08 | 2021-03-23 | 四川大学华西第二医院 | 多聚adp核糖聚合酶抑制剂治疗乙肝病毒相关疾病的新用途 |
| US20180164317A1 (en) * | 2015-05-28 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels |
| WO2017015027A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| EP3331905B1 (en) | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EA033679B1 (ru) | 2015-09-02 | 2019-11-15 | Glaxosmithkline Ip No 2 Ltd | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| JP6795588B2 (ja) | 2015-09-22 | 2020-12-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド |
| ES2831322T3 (es) | 2015-10-05 | 2021-06-08 | Glaxosmithkline Ip No 2 Ltd | Compuestos de 2-oxo-1,2-dihidropiridin-3,5-dicarboxamida como inhibidores de bromodominios |
| EP4050005B1 (en) | 2015-11-25 | 2024-12-25 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| CA3019342A1 (en) | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
| AU2017245641A1 (en) | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109153646B (zh) * | 2016-05-24 | 2022-08-02 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的吡啶二甲酰胺衍生物 |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| US11311609B2 (en) | 2017-02-08 | 2022-04-26 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| EP3596117A4 (en) | 2017-03-17 | 2021-01-13 | The Johns Hopkins University | TARGETED EPIGENETIC THERAPY AGAINST THE DISTAL EXPRESSION REGULATORY ELEMENT OF TGFB2 |
| US11759533B2 (en) | 2017-03-29 | 2023-09-19 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| KR20210003804A (ko) | 2018-04-13 | 2021-01-12 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레브론 리간드 및 이를 포함하는 2작용성 화합물 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| US20220089609A1 (en) | 2018-07-26 | 2022-03-24 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| CN109350616B (zh) * | 2018-12-18 | 2020-04-21 | 南华大学 | I-brd9或其衍生物在制备抗癫痫药物中的应用 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| EP3958867B1 (en) * | 2019-04-24 | 2024-06-26 | Convergene Llc | Small molecule bromodomain inhibitors and uses thereof |
| WO2021107656A2 (ko) * | 2019-11-26 | 2021-06-03 | 주식회사 베노바이오 | 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도 |
| KR102420263B1 (ko) * | 2019-11-26 | 2022-07-13 | 주식회사 베노바이오 | 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도 |
| CN111012786B (zh) * | 2019-12-16 | 2021-05-25 | 中山大学 | 一种激活炎症小体的小分子化合物及其应用 |
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| CN113754593B (zh) * | 2020-06-01 | 2024-03-19 | 上海中医药大学 | 一种brd4蛋白抑制剂及其应用 |
| JP2023539931A (ja) * | 2020-09-09 | 2023-09-20 | オーリジーン オンコロジー リミテッド | Ｃｂｐ／ｅｐ３００ブロモドメイン阻害剤としての複素環式化合物 |
| CN112546049A (zh) * | 2020-12-22 | 2021-03-26 | 中山大学中山眼科中心 | 一种小分子药物(+)-jq1在治疗地图样萎缩型年龄相关性黄斑变性药物中的应用 |
| CN113754594B (zh) * | 2021-09-16 | 2025-01-21 | 中国药科大学 | 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 |
| KR20240045472A (ko) * | 2022-09-30 | 2024-04-08 | 주식회사 베노바이오 | 퀴나졸린염 화합물을 포함하는 관절염 치료용 조성물 및 이의 제조 방법 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3508258A1 (de) | 1985-03-08 | 1986-09-18 | Bayer Ag, 5090 Leverkusen | Ss-lactamantibiotika, verfahren zur herstellung und ihre verwendung als und in arzneimitteln |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| RU1836357C (ru) | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами |
| DE4225756A1 (de) | 1992-01-22 | 1994-03-10 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4224752A1 (de) | 1992-04-11 | 1994-02-03 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5614519A (en) | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
| US5125961A (en) | 1991-08-12 | 1992-06-30 | Monsanto Company | Substituted pyridine compounds |
| DE4219534A1 (de) | 1992-02-19 | 1993-12-16 | Thomae Gmbh Dr K | Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4408497A1 (de) | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO1996004274A1 (en) | 1994-08-02 | 1996-02-15 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives |
| JP3342874B2 (ja) | 1995-04-21 | 2002-11-11 | ニューロサーチ、アクティーゼルスカブ | ベンズイミダゾール化合物、およびｇａｂａａレセプター複合体モジュレーターとしてのその使用 |
| JP2000072675A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| CA2349616A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| GB0002100D0 (en) | 2000-01-28 | 2000-03-22 | Novartis Ag | Organic compounds |
| WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| US20120028912A1 (en) | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| IL155510A0 (en) | 2000-10-27 | 2003-11-23 | Dow Agrosciences Llc | Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones, and their use as fungicides and insecticides |
| CA2430577A1 (en) | 2000-12-01 | 2002-07-25 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
| WO2002072576A1 (en) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| DE60221368T2 (de) | 2001-03-15 | 2008-04-17 | Janssen Pharmaceutica N.V. | Hiv hemmende pyrazinon-derivate |
| JP4329003B2 (ja) | 2001-03-23 | 2009-09-09 | バイエル コーポレイション | Ｒｈｏキナーゼ阻害剤 |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| RU2003131693A (ru) | 2001-03-28 | 2005-05-10 | Бристол-Маерс Сквибб Компани (Us) | Новые ингибиторы тирозин киназ |
| US20050176858A1 (en) | 2002-02-15 | 2005-08-11 | Bridgestone Corporation | Rubber composition and pneumatic tire made therefrom |
| TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| AR043063A1 (es) | 2002-12-13 | 2005-07-13 | Altana Pharma Ag | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003902860A0 (en) | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
| AU2004263190A1 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| WO2005080380A1 (en) | 2004-02-03 | 2005-09-01 | Eli Lilly And Company | Kinase inhibitors |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| JP4627315B2 (ja) | 2004-03-23 | 2011-02-09 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体 |
| US20080015196A1 (en) | 2004-04-16 | 2008-01-17 | Neurogen Corporation | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands |
| JP4991527B2 (ja) | 2004-06-01 | 2012-08-01 | ユニバーシティ オブ バージニア パテント ファンデーション | 二つの部分からなる低分子量の癌および血管新生の抑制剤 |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| EP1786777A1 (en) | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| EP1848718B1 (en) | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| EP1881966A2 (en) | 2005-05-03 | 2008-01-30 | Dow AgroSciences LLC | Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-trianzin-6-ones, and their use as fungicides |
| NZ566180A (en) | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| RU2008112691A (ru) | 2005-10-03 | 2009-10-10 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение |
| US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| AU2006319247B2 (en) | 2005-12-01 | 2010-03-11 | F. Hoffmann-La Roche Ag | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors |
| MX2008010611A (es) | 2006-02-17 | 2008-11-12 | Pfizer Ltd | Derivados de 3-desazapurina como moduladores de receptores similares a toll. |
| CN101384593A (zh) | 2006-02-17 | 2009-03-11 | 辉瑞有限公司 | 用作tlr7调节剂的3-脱氮嘌呤衍生物 |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| CA2700988A1 (en) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| MX2009006312A (es) | 2006-12-14 | 2009-08-07 | Astellas Pharma Inc | Compuestos de acido policiclico utiles como antagonistas crth2 y agentes antialergicos. |
| SG144809A1 (en) | 2007-01-11 | 2008-08-28 | Millipore U K Ltd | Benzimidazole compounds and their use as chromatographic ligands |
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| WO2008153701A1 (en) | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| CN101687815A (zh) | 2007-06-26 | 2010-03-31 | 塞诺菲-安万特股份有限公司 | 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成 |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| GB0719235D0 (en) | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| WO2009054790A1 (en) | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| CA2708262A1 (en) | 2007-12-07 | 2009-06-18 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating liquid tumors |
| US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2009158258A1 (en) | 2008-06-25 | 2009-12-30 | E. I. Du Pont De Nemours And Company | Herbicidal dihydro oxo six-membered azinyl isoxazolines |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| EA201170349A1 (ru) | 2008-08-18 | 2011-08-30 | Йейл Юниверсити | Модуляторы mif |
| US8877772B2 (en) | 2008-11-25 | 2014-11-04 | University Of Rochester | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
| PL2370413T3 (pl) | 2008-12-08 | 2016-01-29 | Arena Pharm Inc | Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| EP2406236A4 (en) | 2009-03-09 | 2013-07-24 | Surface Logix Inc | INHIBITORS OF RHO KINASE |
| NZ595747A (en) * | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS |
| EP2421533B1 (en) | 2009-04-22 | 2018-10-17 | Resverlogix Corp. | Novel anti-inflammatory agents |
| JP5466292B2 (ja) | 2009-05-05 | 2014-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピリジン誘導体 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| ES2652304T3 (es) | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| US9102677B2 (en) | 2009-11-05 | 2015-08-11 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| WO2011062437A2 (ko) | 2009-11-20 | 2011-05-26 | 에스케이케미칼주식회사 | 고나도트로핀 방출 호르몬 수용체 길항제, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| KR101165996B1 (ko) | 2010-04-23 | 2012-07-18 | 주식회사 녹십자 | 프탈라지논 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| WO2011156626A1 (en) | 2010-06-09 | 2011-12-15 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| WO2011159926A1 (en) | 2010-06-16 | 2011-12-22 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| WO2012003576A1 (en) | 2010-07-06 | 2012-01-12 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| EP2603079B1 (en) | 2010-08-12 | 2018-09-19 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| WO2012040499A2 (en) | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| KR101242572B1 (ko) | 2010-10-12 | 2013-03-19 | 한국화학연구원 | 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물 |
| GB201018147D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Method of treatment |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| CN102731409A (zh) | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| LT2773354T (lt) * | 2011-11-01 | 2019-08-12 | Resverlogix Corp. | Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos |
| JP6141863B2 (ja) | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換ベンズイミダゾール及びベンゾピラゾール |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CA2870931A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Isoindolone derivatives |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TR201807207T4 (tr) | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| BR112015004858A2 (pt) | 2012-09-05 | 2017-07-04 | Bayer Cropscience Ag | uso de 2-amidobenzimidazóis, 2-amidobenzoxazóis e 2-amidobenzotiazóis substituídos ou sais dos mesmos como substâncias ativas contra estresse abiótico em plantas |
| US20150246888A1 (en) | 2012-09-11 | 2015-09-03 | Michael Johnson | Enoyl reductase inhibitors with antibacterial activity |
| ES2625945T3 (es) | 2012-11-14 | 2017-07-21 | Glaxosmithkline Llc | Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| EP2935261A1 (de) | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| WO2014128111A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
| WO2014128070A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2961747B1 (en) | 2013-02-27 | 2017-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| JP2016512524A (ja) | 2013-03-11 | 2016-04-28 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| CN105377851B (zh) | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法 |
| HK1218909A1 (zh) | 2013-03-12 | 2017-03-17 | Abbvie Inc. | 二氢-吡咯并吡啶酮布罗莫结构域抑制剂 |
| CN105164113B (zh) | 2013-03-12 | 2018-03-02 | 艾伯维公司 | 吡咯酰胺抑制剂 |
| WO2014140077A1 (en) | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
| ES2704048T3 (es) | 2013-03-14 | 2019-03-14 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio |
| EP2968360B1 (en) | 2013-03-14 | 2021-01-20 | ConverGene LLC | Quinolinone derivatives for the inhibition of bromodomain-containing proteins |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US20160039842A1 (en) | 2013-03-15 | 2016-02-11 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| EP2978758B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Dihydroquinazolinone analogues as brd4 inhibitors |
| US9102684B2 (en) | 2013-03-27 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Indolinone analogues |
| TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類 |
| EP2792355A1 (en) | 2013-04-17 | 2014-10-22 | Albert-Ludwigs-Universität Freiburg | Compounds for use as bromodomain inhibitors |
| WO2014170350A1 (en) | 2013-04-17 | 2014-10-23 | Albert Ludwigs Universität Freiburg | Compounds for use as bromodomain inhibitors |
| CA2901083A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EP3004109A1 (en) | 2013-05-27 | 2016-04-13 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| CA2915419A1 (en) | 2013-06-17 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted phenyl-2,3-benzodiazepines |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CN105407888B (zh) | 2013-06-21 | 2019-05-21 | 齐尼思表观遗传学有限公司 | 新双环溴结构域抑制剂 |
| AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| JP2016525135A (ja) | 2013-07-23 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | ＢＥＴタンパク質およびポロ様キナーゼの二重阻害薬としての置換されたジヒドロピリド［３，４−ｂ］ピラジノン類 |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| BR112016011024B1 (pt) | 2013-11-18 | 2020-09-01 | Forma Therapeutics, Inc | Composto, composição farmacêutica, e, usos dos mesmos |
| WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| WO2016097870A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Substituted bicyclic compounds as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
-
2014
- 2014-07-30 JP JP2016530632A patent/JP6542212B2/ja active Active
- 2014-07-30 CN CN201480053771.5A patent/CN105593224B/zh active Active
- 2014-07-30 US US14/908,898 patent/US9855271B2/en active Active
- 2014-07-30 WO PCT/IB2014/002510 patent/WO2015015318A2/en not_active Ceased
- 2014-07-30 EP EP14832298.5A patent/EP3027604B1/en not_active Not-in-force
- 2014-07-30 EA EA201690087A patent/EA201690087A1/ru unknown
- 2014-07-30 CA CA2919948A patent/CA2919948C/en not_active Expired - Fee Related
- 2014-07-30 KR KR1020167005227A patent/KR20160038008A/ko not_active Withdrawn
- 2014-07-30 AU AU2014298051A patent/AU2014298051B2/en not_active Ceased
-
2016
- 2016-01-04 IL IL243479A patent/IL243479B/en not_active IP Right Cessation
-
2017
- 2017-11-22 US US15/821,454 patent/US10500209B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527263A5 (enExample) | ||
| WO2015015318A4 (en) | Novel quinazolinones as bromodomain inhibitors | |
| JP2016522246A5 (enExample) | ||
| AU2021240103B2 (en) | Substituted pyrrolizine compounds and uses thereof | |
| US12357603B2 (en) | Acyl sulfonamides for treating cancer | |
| JP2016525078A5 (enExample) | ||
| KR102411150B1 (ko) | 세포 대사 과정의 억제제 | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| US20220274979A1 (en) | 2-methyl-aza-quinazolines | |
| US10729680B2 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| US10130633B2 (en) | Compounds | |
| CN1307179C (zh) | 抑制细胞增殖的嘧啶衍生物 | |
| US10428044B2 (en) | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | |
| JP2017538721A5 (enExample) | ||
| JP2017537946A5 (enExample) | ||
| CN114555588B (zh) | 作为axl抑制剂的喹唑啉类化合物 | |
| CN111386118A (zh) | 作为rsv抑制剂的组合药物剂 | |
| SK12002003A3 (en) | Novel tyrosine kinase inhibitors | |
| HRP20200854T1 (hr) | Novi biciklički inhibitori bromodomene | |
| JP2017532360A5 (enExample) | ||
| US9586956B2 (en) | Isoquinoline and naphthyridine derivatives | |
| CA2577185A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| EP3570832A2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| US10894784B2 (en) | Heteroarylbenzimidazole compounds | |
| EP4192830A1 (en) | 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy |